New EU Filings
A Regularly Updated List Of New Marketing Authorization Applications At The EMA
Executive Summary
Janssen/Legend Biotech's ciltacabtagene autoleucel and Ipsen's palovarotene are among the latest new medicines that have been submitted for pan-EU approval.
You may also be interested in...
Phase III Analyses Prompt Partial Clinical Hold On Oncopeptides' Melflufen Studies
Oncopeptides AB’s melflufen (Pepaxto) has met the primary PFS endpoint in the Phase III OCEAN study, designed to extend its reach into earlier-stage multiple myeloma patients, but overall survival data favors the comparator in patient subgroups, and melflufen in others, leading to regulators pausing clinical trials to review the results.
Roche’s Novel Ranibizumab Implant Among Myriad New Filings In EU
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.